| JNJ |
Report |
Q2 2026 revenue |
BEAT |
pred ~$25.34B vs. cons $25.03B |
MEDIUM |
| JNJ |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$2.90 vs. cons $2.86 |
MEDIUM |
| JNJ |
Report |
Q2 2026 MedTech sales |
IN-LINE |
pred ~$8.94B vs. cons $8.90B |
MEDIUM |
| JNJ |
Guide |
Operational sales |
BETTER |
guide ~$100.6B vs. cons $100.5B (FY2026) |
MEDIUM |
| JNJ |
Guide |
Reported adjusted EPS |
BETTER |
guide ~$11.62 vs. cons $11.58 (FY2026) |
MEDIUM |
| JNJ |
Guide |
Adjusted pretax operating-margin expansion |
UNCHANGED |
guide ~+50 bps vs. cons +50 bps (FY2026) |
MEDIUM |
| JNJ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.4% |
— |
MEDIUM |
| JNJ |
Return |
5-day cumulative residual |
+0.6% (FADE) |
5-day residual ~+0.6% vs. day-1 residual +1.4%: a modest beat and raise should lift estimates, but limited second-half EPS flow-through and some FX contribution to the sales raise imply only small out-period revisions, allowing the high-valuation initial reaction to partially fade. |
MEDIUM |